These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 26188340

  • 1. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E, Jones M, Hourigan MJ, Johnson DW, Gill DS, Isbel N, Hawley CM, Marlton P, Gandhi MK, Campbell SB, Mollee P.
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [Abstract] [Full Text] [Related]

  • 2. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J.
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M, Marciano S, dos Santos Schraiber L, Zapata R, Quiros R, Zanotelli ML, Rivas MM, Kusminsky G, Humeres R, Alves de Mattos A, Gadano A, Silva MO.
    Clin Transplant; 2013 Sep; 27(4):E469-77. PubMed ID: 23758407
    [Abstract] [Full Text] [Related]

  • 4. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
    Serre JE, Michonneau D, Bachy E, Noël LH, Dubois V, Suberbielle C, Kreis H, Legendre C, Mamzer-Bruneel MF, Morelon E, Thaunat O.
    Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA, Hamilton-Dutoit S, Bendtzen K.
    Transplantation; 2003 Jul 15; 76(1):153-8. PubMed ID: 12865802
    [Abstract] [Full Text] [Related]

  • 6. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 7. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB, Wang Y, Song QJ, Shen DH.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep 27; 41(9):607-12. PubMed ID: 23157829
    [Abstract] [Full Text] [Related]

  • 8. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
    Zierhut H, Kanzelmeyer N, Buescher A, Höcker B, Mauz-Körholz C, Tönshoff B, Metzler M, Pohl M, Pape L, Maecker-Kolhoff B.
    Pediatr Transplant; 2021 Sep 27; 25(6):e14042. PubMed ID: 34021949
    [Abstract] [Full Text] [Related]

  • 9. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R, Shapiro R, Jordan ML, Scantlebury VP, Gritsch HA, Vivas C, Randhawa PS.
    Clin Transplant; 1997 Dec 27; 11(6):574-6. PubMed ID: 9408687
    [Abstract] [Full Text] [Related]

  • 10. Post-transplant lymphoproliferative disorders (PTLD) after renal transplantation: management and evolution of seven cases among 1002 renal transplants in São Paulo, Brazil.
    Colleoni GW, Oliveira JS, Borducchi DM, Fernandes MA, Da Silva HT, Alves AC, De Franco MF, Kerbauy J, Pestana JO.
    Leuk Lymphoma; 2000 Sep 27; 39(1-2):145-50. PubMed ID: 10975393
    [Abstract] [Full Text] [Related]

  • 11. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim HN, Matas AJ, Issa N.
    Clin Transplant; 2016 Jan 27; 30(1):60-5. PubMed ID: 26497471
    [Abstract] [Full Text] [Related]

  • 12. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.
    Transplantation; 2018 Nov 27; 102(11):1914-1923. PubMed ID: 29757894
    [Abstract] [Full Text] [Related]

  • 13. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 27; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 14. Long-term survival after post-transplant lymphoproliferative disease in children.
    Nathanson S, Debray D, Delarue A, Deschênes G.
    Pediatr Nephrol; 2002 Aug 27; 17(8):668-72. PubMed ID: 12185479
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan 27; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 16. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 27; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 17. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct 27; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 18. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.
    Transplantation; 2007 Apr 15; 83(7):912-8. PubMed ID: 17460562
    [Abstract] [Full Text] [Related]

  • 19. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Nephrol Dial Transplant; 2012 Jul 15; 27(7):2971-9. PubMed ID: 22273720
    [Abstract] [Full Text] [Related]

  • 20. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.
    J Heart Lung Transplant; 2010 Jun 15; 29(6):648-57. PubMed ID: 20304682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.